ABBOTT LABORATORIES acquires CFR Pharmaceuticals S.A.
The deal at a glance
ABBOTT LABORATORIES acquired CFR Pharmaceuticals S.A. for approximately $2.9 billion, a transaction completed in September 2014, structured as all cash (tender offer).
CFR Pharmaceuticals S.A. operates in Pharmaceuticals — branded generics, is based in Santiago, Chile (Latin America). CFR Pharmaceuticals is a Latin America-based branded generics pharmaceutical company with a broad portfolio of well-known, trusted products and a strong presence across the fast-growing region.
By adding CFR's portfolio of well-known, trusted products, Abbott has taken another key step in actively shaping its portfolio to better meet the evolving needs of healthcare in Latin America, more than doubling its branded generics sales in the region.
More than doubled Abbott's branded generics sales and presence in the fast-growing Latin American market. Integrated into Abbott's Established Pharmaceuticals business
No advisory firms have been disclosed for this transaction.